Compounds > hedamycin
Page last updated: 2024-11-07

hedamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID98033
CHEMBL ID1979887
MeSH IDM0041460

Synonyms (23)

Synonym
antibiotic b26158
nsc 70929
4h-anthra(1,2-b)pyran-4,7,12-trione, 2-(3,3'-dimethyl(2,2'-bioxiran)-3-yl)-11-hydroxy-5-methyl-8-(2,3,6-trideoxy-3-(dimethylamino)-beta-d-arabino-hexopyranosyl)-10-(2,3,6-trideoxy-3-(dimethylamino)-3-c-methyl-alpha-l-lyxo-hexopyranosyl)-
nsc-70929d
NCI60_038569
11048-97-8
antibiotic b26,158
crystalline antibiotic b 26,158
hedamycin
4h-anthra[1,7,12-trione, 2-(3,3'-dimethyl[2,2'-bioxiran]-3-yl)-11-hydroxy-5-methyl-8-[2,3,6-trideoxy-3-(dimethylamino)-.beta.-d-arabino-hexopyranosyl]-10-[2,3,6-trideoxy-3-(dimethylamino)-3-c-methyl-.alpha.-l-lyxo-hexopyranosyl]-
NSC70929 ,
antiobiotic b 28158, crystalline
nsc-70929
b 26158
10-[4-(dimethylamino)-5-hydroxy-4,6-dimethyl-tetrahydropyran-2-yl]-8-[4-(dimethylamino)-5-hydroxy-6-methyl-tetrahydropyran-2-yl]-11-hydroxy-5-methyl-2-[2-methyl-3-(3-methyloxiran-2-yl)oxiran-2-yl]naphtho[2,3-h]chromene-4,7,12-trione
4h-anthra(1,2-b)pyran-4,7,12-trione, 2-(3,3'-dimethyl(2,2'-bioxiran-3-yl)-11-hydroxy-5-methyl-8-(2,3,6-trideoxy-3-(dimethylamino)-.beta.-d-arabino-hexopyranosyl)-10-(2,3,6-trideoxy-3-(dimethylamino)-3-c-methyl-.alpha.-l-lyxo-hexopyranos yl]-
10-[4-(dimethylamino)-5-hydroxy-4,6-dimethyloxan-2-yl]-8-[4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-11-hydroxy-5-methyl-2-[2-methyl-3-(3-methyloxiran-2-yl)oxiran-2-yl]naphtho[2,3-h]chromene-4,7,12-trione
CHEMBL1979887
B26158 ,
Q15411002
gtpl10958
antibiotic b 26,158
DTXSID301028214

Research Excerpts

Overview

Hedamycin is an antitumor polyketide antibiotic with unusual biosynthetic features.

ExcerptReferenceRelevance
"Hedamycin is an antitumor polyketide antibiotic with unusual biosynthetic features. "( In vivo and in vitro analysis of the hedamycin polyketide synthase.
Das, A; Khosla, C, 2009)		2.07

Treatment

Hedamycin treatment of HCT116 carcinoma cells resulted in a rapid induction of DNA strand breaks accompanied by increasing H2AX phosphorylation and focalization.

ExcerptReferenceRelevance
"Hedamycin treatment at concentrations below its growth IC(50) induced only a transient and temporary accumulation of cells in G(2)."( DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic.
Beerman, TA; Melendy, T; Tu, LC, 2004)		1.27
"Hedamycin treatment of HCT116 carcinoma cells resulted in a rapid induction of DNA strand breaks accompanied by increasing H2AX phosphorylation and focalization."( Hedamycin, a DNA alkylator, induces (gamma)H2AX and chromosome aberrations: involvement of phosphatidylinositol 3-kinase-related kinases and DNA replication fork movement.
Beerman, TA; Matsui, SI; Tu, LC, 2005)		2.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (14.29)18.7374
1990's12 (42.86)18.2507
2000's11 (39.29)29.6817
2010's1 (3.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.85 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
caffeine
[no description available]		2.0210purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
stallimycin
[no description available]		1.9910
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		210nitrogen mustard;
organochlorine compound		alkylating agent
altromycin b
altromycin B: from an actinomycete; structure given in second source		2.3920
nogalamycin
Nogalamycin: An anthrocycline from a Streptomyces nogalater variant. It is a cytolytic antineoplastic that inhibits DNA-dependent RNA synthesis by binding to DNA.. nogalamycin : An anthracycline antibiotic isolated from Streptomyces nogalater. It is a DNA intercalator and exhibits anticancer properties.		2.3920
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.0310
adozelesin
[no description available]		2.0310
actinorhodin
actinorhodin: structure. actinorhodin : A member of the class of benzoisochromanequinone that is produced by Streptomyces coelicolor A3(2) and exhibits antibiotic activity.		2.0610
nanaomycin a
nanaomycin A: produced by a strain OS-3966 of Streptomyces rosa var. notoensis; quinone-related cpd; MF C16-H14-O6; see also nanaomycin B: 52934-85-7, nanaomycin C: 58286-55-8, nanaomycin E: 72660-52-7; structure. nanaomycin A : A pyranonaphthoquinone antibiotic from strain OS-3966 of Streptomyces rosa var. notoensis.		2.0410benzoisochromanequinone;
monocarboxylic acid;
organooxygen heterocyclic antibiotic;
p-quinones		bacterial metabolite
destomycin a
destomycin A: structure given in first source		2.0410
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.0410
quercetin
[no description available]		2.06107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
irumamycin
irumamycin: from Streptomyces subflavus; macrolide antibiotic with sugar moiety		2.0410
ll d42067 alpha
simaomicin alpha: from an actinomycete strain; RN given refers to (7alpha,11beta,14alpha)-(+)-isomer; RN for cpd without isomeric designation not avail 11/90; structure given in first source		2.0310
am 2604a
virustomycin A: from Streptomyces sp. AM-2604		2.0410
aureothin
aureothin: isolated from culture MA-2465; structure. aureothin : A C-nitro compound that is (3Z)-3-[(2E)-2-methyl-3-(4-nitrophenyl)prop-2-en-1-ylidene]tetrahydrofuran which is substituted by a 6-methoxy-3,5-dimethyl-4-oxo-4H-pyran-2-yl group at position 5. It is isolated from the soil bacterium, Streptomyces thioluteus and exhibits antitumor, antifungal, and insecticidal activities.		2.04104-pyranones;
C-nitro compound;
ketene acetal;
olefinic compound;
oxolanes		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor
triacsin c
triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist. triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters.		2.0310hydrazone;
nitroso compound;
olefinic compound		antimalarial;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
vasodilator agent
triacsin d
triacsin D: inhibits long chain acyl-CoA synthetase; from Streptomyces No. 1228; structure given in first source		2.0310
pluramycin
[no description available]		7.420
oligonucleotides
[no description available]		1.9810
echinomycin
Echinomycin: A cytotoxic polypeptide quinoxaline antibiotic isolated from Streptomyces echinatus that binds to DNA and inhibits RNA synthesis.		2.4120cyclodepsipeptide
hygromycin b
[no description available]		2.0410
venturicidin a
venturicidin A: structure given in first source		2.0410
chromomycins
Chromomycins: A complex of several closely related glycosidic antibiotics from Streptomyces griseus. The major component, CHROMOMYCIN A3, is used as a fluorescent stain of DNA where it attaches and inhibits RNA synthesis. It is also used as an antineoplastic agent, especially for solid tumors.. chromomycin : A family of antibiotics isolated from Streptomyces griseus.		1.9810
guanine
[no description available]		7.68302-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
7-deazaguanine
[no description available]		1.9810organic molecular entity
chromomycin a3
Chromomycin A3: Glycosidic antibiotic from Streptomyces griseus used as a fluorescent stain of DNA and as an antineoplastic agent.		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.0210
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0210
Abnormalities, Autosome
[description not available]		02.0210
Di Guglielmo Disease
[description not available]		01.9910
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		01.9910